Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Askew

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Journal of Medicinal Chemistry|June 6, 1997
Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonistsB C Askew, R A Bednar, B Bednar, et al.
Journal of Medicinal Chemistry|September 17, 2004
Nonpeptide alphavbeta3 antagonists. Part 11: discovery and preclinical evaluation of potent alphavbeta3 antagonists for the prevention and treatment of osteoporosisPaul J Coleman, Karen M Brashear, Ben C Askew, et al.
Bioorganic & Medicinal Chemistry Letters|December 12, 2001
Non-peptide alpha(v)beta(3) antagonists. Part 3: identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacementsPaul J Coleman, Karen M Brashear, Cecilia A Hunt, et al.
Bioorganic & Medicinal Chemistry Letters|April 26, 2011
3-Oxo-2-piperazinyl acetamides as potent bradykinin B1 receptor antagonists for the treatment of pain and inflammationJian Jeffrey Chen, Thomas Nguyen, Derin C D'Amico, et al.
Journal of Medicinal Chemistry|April 6, 2007
Potent nonpeptide antagonists of the bradykinin B1 receptor: structure-activity relationship studies with novel diaminochroman carboxamidesKaustav Biswas, Aiwen Li, Jian Jeffrey Chen, et al.
Journal of Medicinal Chemistry|August 2, 2019
Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological DiseasesRichard D Caldwell, Hui Qiu, Ben C Askew, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Journal of Medicinal Chemistry|June 6, 1997
Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonistsB C Askew, R A Bednar, B Bednar, et al.
Journal of Medicinal Chemistry|September 17, 2004
Nonpeptide alphavbeta3 antagonists. Part 11: discovery and preclinical evaluation of potent alphavbeta3 antagonists for the prevention and treatment of osteoporosisPaul J Coleman, Karen M Brashear, Ben C Askew, et al.
Bioorganic & Medicinal Chemistry Letters|December 12, 2001
Non-peptide alpha(v)beta(3) antagonists. Part 3: identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacementsPaul J Coleman, Karen M Brashear, Cecilia A Hunt, et al.
Bioorganic & Medicinal Chemistry Letters|April 26, 2011
3-Oxo-2-piperazinyl acetamides as potent bradykinin B1 receptor antagonists for the treatment of pain and inflammationJian Jeffrey Chen, Thomas Nguyen, Derin C D'Amico, et al.
Journal of Medicinal Chemistry|April 6, 2007
Potent nonpeptide antagonists of the bradykinin B1 receptor: structure-activity relationship studies with novel diaminochroman carboxamidesKaustav Biswas, Aiwen Li, Jian Jeffrey Chen, et al.
Journal of Medicinal Chemistry|August 2, 2019
Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological DiseasesRichard D Caldwell, Hui Qiu, Ben C Askew, et al.
Pageof 4